These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12. Melero I; Quetglas JI; Reboredo M; Dubrot J; Rodriguez-Madoz JR; Mancheño U; Casales E; Riezu-Boj JI; Ruiz-Guillen M; Ochoa MC; Sanmamed MF; Thieblemont N; Smerdou C; Hervas-Stubbs S Cancer Res; 2015 Feb; 75(3):497-507. PubMed ID: 25527611 [TBL] [Abstract][Full Text] [Related]
26. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Colmenero P; Chen M; Castaños-Velez E; Liljeström P; Jondal M Int J Cancer; 2002 Apr; 98(4):554-60. PubMed ID: 11920615 [TBL] [Abstract][Full Text] [Related]
27. Semliki Forest virus (SFV) vectors in neurobiology and gene therapy. Lundstrom K; Ehrengruber MU Methods Mol Med; 2003; 76():503-23. PubMed ID: 12526182 [No Abstract] [Full Text] [Related]
28. Cerebellar glioblastoma multiforme in an adult woman. Sciacero P; Girelli GF; Cante D; Franco P; Casanova Borca V; Grosso P; Marra A; Bombaci S; Tofani S; La Porta MR; Ricardi U Tumori; 2014; 100(3):e74-8. PubMed ID: 25076255 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493 [TBL] [Abstract][Full Text] [Related]
30. Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines. Withoff S; Glazenburg KL; van Veen ML; Kraak MM; Hospers GA; Störkel S; de Vries EG; Wilschut J; Daemen T Gene Ther; 2001 Oct; 8(20):1515-23. PubMed ID: 11704811 [TBL] [Abstract][Full Text] [Related]
31. Potential of alphavirus vectors in the treatment of advanced solid tumors. Kelly BJ; Fleeton MN; Atkins GJ Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):159-66. PubMed ID: 18221060 [TBL] [Abstract][Full Text] [Related]
32. Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells. Lee JS; Lee JH; Poo H; Kim MS; Lee SH; Sung MH; Kim CJ Int J Oncol; 2006 Mar; 28(3):649-54. PubMed ID: 16465369 [TBL] [Abstract][Full Text] [Related]
33. Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon. Vasilevska J; Skrastina D; Spunde K; Garoff H; Kozlovska T; Zajakina A Cancer Gene Ther; 2012 Aug; 19(8):579-87. PubMed ID: 22722377 [TBL] [Abstract][Full Text] [Related]
34. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Shand N; Weber F; Mariani L; Bernstein M; Gianella-Borradori A; Long Z; Sorensen AG; Barbier N Hum Gene Ther; 1999 Sep; 10(14):2325-35. PubMed ID: 10515452 [TBL] [Abstract][Full Text] [Related]
35. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Yamanaka R; Zullo SA; Ramsey J; Onodera M; Tanaka R; Blaese M; Xanthopoulos KG Cancer Gene Ther; 2001 Oct; 8(10):796-802. PubMed ID: 11687903 [TBL] [Abstract][Full Text] [Related]
36. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906 [TBL] [Abstract][Full Text] [Related]
37. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Rainov NG Hum Gene Ther; 2000 Nov; 11(17):2389-401. PubMed ID: 11096443 [TBL] [Abstract][Full Text] [Related]
38. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188 [TBL] [Abstract][Full Text] [Related]
39. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus. Ramachandran M; Yu D; Dyczynski M; Baskaran S; Zhang L; Lulla A; Lulla V; Saul S; Nelander S; Dimberg A; Merits A; Leja-Jarblad J; Essand M Clin Cancer Res; 2017 Mar; 23(6):1519-1530. PubMed ID: 27637889 [No Abstract] [Full Text] [Related]
40. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. Weber F; Asher A; Bucholz R; Berger M; Prados M; Chang S; Bruce J; Hall W; Rainov NG; Westphal M; Warnick RE; Rand RW; Floeth F; Rommel F; Pan H; Hingorani VN; Puri RK J Neurooncol; 2003; 64(1-2):125-37. PubMed ID: 12952293 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]